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doi:10.1016/j.hkjn.2012.03.001Summary Malignancy is considered to be the third most common cause of death in renal
transplant recipients. The etiology of posttransplantation malignancy seems to be multifacto-
rial. This report describes a rare case of astrocytoma following renal transplantation. We
encountered a 28-year-old man who presented with a 20-day history of headache, vomiting,
and blurred vision prior to admission. The patient was diagnosed with end-stage renal disease
and underwent two renal transplantations at 8 and 2 years prior, respectively. Examination of
the cerebrospinal fluid revealed a predominant lymphocytic pattern and increased protein
levels. Brain imaging showed two separate ill-defined hypodense lesions. The patient under-
went a stereotactic brain biopsy, from which the tumor was classified as a histological grade
II astrocytoma. He received a course of radiotherapy treatments and his condition improved.
The systematic screening of renal transplant recipients for cancer should be performed in
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g Kong Society of Nephrology LtdIntroduction
The development of malignancy is a well-recognized
complication of organ transplantation.1 Renal trans-
plantation is the treatment of choice for patients with
end-stage renal disease (ESRD),2 but these recipients are. Published by Elsevier Taiwan LLC. All rights reserved.
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than the general population.3 Malignancy is considered to
be the third most common cause of death in renal trans-
plant recipients. One of the contributing factors may be
immunosuppressive therapy, which can support oncogenic
viruses and impair immune surveillance.4 There are three
situations in which malignancy typically occurs: malignancy
is transmitted via the donor, a known or latent prior
malignancy has already developed in the recipient, and de
novo malignancy that develops in the recipient after
transplantation.5 A large percentage of the tumors involve
the central nervous system, but cases of glioma are less
frequent.6 The World Health Organization (WHO) grading
system is used to classify these tumors into prognostically
meaningful grades.7 Therefore, screening, early diagnosis,
and treatment of malignancies are important strategies
that must be implemented after renal transplantation in
order to improve the survival time and quality of life of
these patients.3 Nevertheless, little attention has been
paid to posttransplantation astrocytomas and an exact
evaluation of this risk is still lacking. Here, we describe
a rare case of astrocytoma in a patient who underwent
renal transplantation. To the best of our knowledge, this is
the first reported case of astrocytoma following renal
transplantation.Case report
A 28-year-old man was referred to Alzahra Hospital, an
affiliate of Isfahan University of Medical Sciences, Isfahan,
Iran, with a 20-day history of frontal headache, projectile
vomiting, and neck pain. Other medical conditions
included a low-grade fever and weight loss. His vision had
recently become blurred in the right eye. In April 2003, the
patient received a renal transplant from his 33-year-old
brother to treat ESRD due to chronic pyelonephritis. He had
human leukocyte antigen (HLA) matching with his brother.
After transplantation, he was under treatment that con-
sisted of an immunosuppressive regimen of cyclosporine,
prednisolone, and mycophenolate mofetil. In July 2009, he
underwent a second left renal transplant for graft failure,Figure 1 Brain CT scan showing two separate ill-defined hypode
right frontal lobe.which was donated by a living donor, followed by immu-
nosuppressive therapy. Upon admission, remarkable find-
ings on physical examination included an oral temperature
of 38.5C and a heart rate of 120 beats/minute. In the
preceding month, he had developed elevated blood urea
nitrogen (BUN) and plasma creatinine levels. Ultrasonog-
raphy revealed obstructive nephropathy due to posttrans-
plant compressive lymphocele, which was treated by
drainage of the lymphocele. The patient underwent a full
workup that included determination of serum chemistries,
blood culture, urine examinations, chest radiography, brain
imaging, lumbar puncture, and fundoscopic examination.
Hemoglobin, liver enzyme, and coagulation tests were
normal. Blood culture and all tests conducted to determine
infectious diseases were negative. No cardiovascular or
pulmonary abnormalities were found. His urological evalu-
ation was unremarkable and his graft was functioning well.
Although serologic testing showed no signs of acute infec-
tion, broad-spectrum empiric antibiotics for meningitis
were administered. A lumbar puncture was performed in an
attempt in control the cerebrospinal fluid (CSF) pressure.
CSF studies revealed a predominant lymphocytic pattern
and increased protein levels. Guided by our patient’s
history, we agreed with the referring neurologist and sus-
pected malignancy. The neurological examination noted
headache, blurred vision, raised intracranial pressure,
recent hearing loss, and left 6th cranial nerve palsy.
Computerized tomography (CT) was performed, which
demonstrated two separate ill-defined hypodense lesions:
one was located in the left temporal lobe and the other was
located in the right frontal lobe. Evidence of brain edema in
both parietal lobes was also present (Fig. 1). Brain magnetic
resonance imaging (MRI) was performed, which revealed
hypodense lesions. The patient was transferred to the
neurosurgical section where a stereotactic brain biopsy was
taken. Microscopic sections indicated an infiltrating astro-
cytic neoplasm that exhibited mild nuclear pleomorphism
and modest hyperchromasia. The absence of mitotic
activity, necrosis, or vascular proliferation with endothelial
hyperplasia led us to a diagnosis of grade II astrocytoma
(Fig. 2).Upon diagnosis, the patient received a course of
radiotherapy treatments and we noted continuednse lesions: one in the left temporal lobe and the other in the
Figure 2 Infiltrating astrocytic neoplasm exhibiting mild
nuclear pleomorphism and modest hyperchromasia. No
mitoses, necrosis, or vascular proliferation are present. (H&E
staining, 100 and 400 magnification, respectively).
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discharged 3 weeks later and remains well on follow-up
examinations.Discussion
A significantly increased incidence of neoplasia is well
documented in renal transplant recipients and is a major
cause of morbidity and mortality in transplant patients.8
There is sufficient evidence that 40% of renal graft recipi-
ents develop cancer after 20 years,9 which may be related
to impaired immunosurveillance, the direct neoplastic
actions of immunosuppressive agents, oncogenic viruses,
or genetic predisposition.3 This increase in risk is not the
same for all types of malignancies following renal trans-
plantation. Periodic screening and strict adherence to
prophylactic measures help to prevent and detect cancers
in transplant patients.10 These approaches should start with
the screening of donors for cancer, thereby minimizing the
required dose of immunosuppressive drugs,4 the consump-
tion of prophylactic antiviral drugs,11 and the avoidance of
carcinogenic factors such as high sun exposure.12 Several
types of cancers present in renal transplant populations,including skin cancers,10 posttransplant lymphoprolifer-
ative disorders (PTLD), multiple myeloma,13 non-Hodgkin’s
lymphoma,14 Kaposi’s sarcoma,15 colorectal cancer,16 and
renal cell carcinoma.17 Reported cases of brain tumors in
the posttransplantation setting include lymphomas, glio-
blastomas, and oligodendrogliomas.18 Our patient’s final
diagnosis was grade II astrocytoma, which is an unexpected
cancer in this context. According to our review of the
literature, this seems to be a rare case. Grade II astrocy-
toma is characterized by an intrinsic tendency for local
recurrence and spontaneous progression to high-grade
anaplastic astrocytoma.19
Our patient was immunosuppressed following renal
transplantation. This finding has been previously confirmed,
specifically that cancers are more than 100 times as likely
to develop in organ transplant recipients than in the
general population or patients on waiting lists.18 Our
experience is in agreement with the findings reported by
Salvati et al. These authors reported five cases of glio-
blastoma in kidney transplant recipients who presented
4e7 years after transplantation.6 The time period by which
most cancers develop posttransplantation also varies with
the nature of the malignancy.10 In the present case, the
astrocytomas were located in the left temporal and right
frontal lobes. Malhan et al highlighted that most cases of
grade II astrocytoma are located in the frontal and fron-
totemporal regions.7
In conclusion, we have presented a unique case of
astrocytoma after renal transplantation, which illustrates
several interesting aspects. First, the risk of developing
rare malignancies is increasingly recognized in transplant
recipients.20 Second, malignancies in renal transplant
recipients can vary in terms of prevalence and tumor
behavior. Finally, renal transplant recipients need to
regularly undergo screening tests in order to detect tumors
after transplantation and enable early intervention when-
ever necessary. In addition, astrocytoma must be consid-
ered in the differential diagnosis of space-occupying lesions
in transplant recipients.References
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